• Mon. Jun 17th, 2024

FDA Issues Warning Letters to Six Companies for Marketing Dangerous Lidocaine Topicals

BySamantha Johnson

Mar 27, 2024
Popular Pain-Relief Creams Pose Dangerous Health Risks, FDA Warns

In recent news, the U.S. Food and Drug Administration (FDA) has issued warning letters to six companies for marketing unapproved, misbranded products with higher-than-allowed concentrations of lidocaine. These popular over-the-counter topical pain-relief products are often used in conjunction with cosmetic procedures, but the FDA is sounding the alarm on their potentially dangerous side effects.

According to the FDA, these products pose unacceptable risks to consumers and should not be on the market. The problem with these products is that they have too much lidocaine, which can cause serious side effects like an irregular heartbeat, seizures, and breathing issues. Furthermore, if used on a large portion of skin or irritated skin, it can cause serious injury.

If you are going to use a product containing local anesthetics, the FDA recommends not using anything containing more than 4% lidocaine, not using it on large areas of skin, and not wrapping the product onto the skin with dressings or plastic wraps. It’s important to follow these guidelines to avoid any potential harm from these high-risk products.

The products in question include TKTX Numb Maximum Strength Pain Reliever, TKTX During Procedure Numbing Gel and J-CAIN cream, NumbSkin Lidocaine Numbing Creams, Signature Tattoo Numbing Cream and Miracle Numb Spray, Painless Tattoo Numbing Cream and Painless Tattoo Numbing Spray

By Samantha Johnson

As a dedicated content writer at newsanguinely.com, I weave words into compelling stories that captivate and inform our readers. With a passion for storytelling and a keen eye for detail, I craft engaging articles that shed light on the latest news and trends. When I'm not typing away at my keyboard, you can find me exploring new ideas, researching diverse topics, and striving to deliver content that resonates with our audience. Join me on this journey as we uncover the stories that matter most.

Leave a Reply